Joel Russell
Editor
Joel Russell is editor of the Business Journal and is responsible for the content of the publication.
Phone: 818-316-3125 Extension: 116
Recent Stories
California Resources to Sell $600 Million in Senior Notes
California Resources Corp. intends to sell $600 million in unsecured senior notes with repayment due in 2026.
VALLEY INSIDER
Gaines Gets Tribute
At its Dec. 2 meeting on Zoom, the Calabasas City Council recognized Fred Gaines for his service.
Wealth Managers’ Wild Ride
Financial advisors weathered market downs and ups during a year of surprises.
The onset of the coronavirus caused one of the sharpest nosedives in the history of global capital markets. Between Feb. 20 and April 7, the Nasdaq tumbled an unprecedented 1,864 points, a loss of nearly 20 percent.
Valley Kaiser Permanente Staff to Appear in Rose Parade TV Segment
Staff from Valley facilities of Kaiser Permanente will participate in the health care organization’s 90-second video for “The Rose Parade’s New Year Celebration presented by Honda” on New Year’s Day.
Amgen Licenses Experimental Drug for Tuberculosis, Leprosy Treatment
Amgen Inc. has licensed one of its investigational pipeline drugs to Medicines Development for Global Health for the treatment of tuberculosis and leprosy.
Fox & Hounds Daily to Shut Down
Joel Fox, co-publisher of the conservative political website Fox & Hounds Daily, plans to close the site.
Chambers of Commerce Send Letter to State Officials
A coalition of chambers of commerce – including many in the Valley region – plan to send a letter to state elected officials Thursday voicing their concerns about the latest stay-at-home orders.
Location Filming Declines in November
For the first time since movie production in Los Angeles County reopened in June, location filming decreased in November.
Down Year Deal-Making
Coronavirus slowed M&A activity in 2020, but now companies are looking forward to the post-pandemic economy.
After several years of furious deal-making in the Valley, 2020 represented a pause. There were no equivalents of Walt Disney Co.’s $71 billion purchase of 20th Century Fox or Amgen Inc.’s acquisition of the drug Otezla for $13.4 billion, both deals from 2019.